Swedbank AB Sells 3,101 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Swedbank AB lowered its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 2.8% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 109,409 shares of the company’s stock after selling 3,101 shares during the quarter. Swedbank AB’s holdings in Teva Pharmaceutical Industries were worth $1,972,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Quadrature Capital Ltd bought a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter worth $203,000. Park Avenue Securities LLC bought a new stake in Teva Pharmaceutical Industries in the 1st quarter worth about $248,000. Range Financial Group LLC purchased a new stake in Teva Pharmaceutical Industries in the 1st quarter valued at about $797,000. Atlas Capital Advisors LLC lifted its position in shares of Teva Pharmaceutical Industries by 3,427.6% during the 1st quarter. Atlas Capital Advisors LLC now owns 43,742 shares of the company’s stock worth $617,000 after buying an additional 42,502 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. boosted its stake in shares of Teva Pharmaceutical Industries by 30.3% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 206,162 shares of the company’s stock worth $2,909,000 after buying an additional 47,954 shares during the last quarter. 54.05% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Teva Pharmaceutical Industries news, insider Eric A. Hughes sold 24,537 shares of the firm’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $17.25, for a total value of $423,263.25. Following the completion of the transaction, the insider now owns 45,060 shares in the company, valued at $777,285. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.55% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of analysts recently commented on TEVA shares. Jefferies Financial Group increased their price target on Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the company a “buy” rating in a research report on Thursday, June 27th. UBS Group raised their target price on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Thursday. Argus upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 price objective for the company in a report on Wednesday, July 10th. Finally, Barclays boosted their target price on shares of Teva Pharmaceutical Industries from $21.00 to $22.00 and gave the company an “overweight” rating in a research note on Thursday, August 1st. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Teva Pharmaceutical Industries currently has a consensus rating of “Moderate Buy” and an average price target of $18.89.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE:TEVA opened at $17.96 on Friday. The company has a 50-day moving average price of $17.97 and a two-hundred day moving average price of $16.61. Teva Pharmaceutical Industries Limited has a twelve month low of $8.06 and a twelve month high of $19.08. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 2.52. The firm has a market capitalization of $20.34 billion, a PE ratio of -46.04, a P/E/G ratio of 1.20 and a beta of 0.88.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Wednesday, July 31st. The company reported $0.58 earnings per share for the quarter, beating analysts’ consensus estimates of $0.55 by $0.03. The business had revenue of $4.16 billion during the quarter, compared to analyst estimates of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 2.73% and a positive return on equity of 39.66%. Equities analysts forecast that Teva Pharmaceutical Industries Limited will post 2.33 EPS for the current year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.